LXEO Lexeo Therapeutics

Lexeo Acquires Mantle Therapeutics and Announces FA Collaborations

Lexeo signed a definitive agreement to acquire Mantle Therapeutics (adding oral and protein-replacement modalities for frataxin restoration in the brain) and entered three research/option collaborations to evaluate cerebellar-targeted sequential dosing after LX2006. SUNRISE-FA 2 pivotal trial for LX2006 remains on track for topline data in H2 2027.

Lexeo finalizes SUNRISE-FA 2 pivotal protocol for LX2006 in FA cardiomyopathy

Lexeo finalized the SUNRISE-FA 2 open-label pivotal protocol and SAP for LX2006, with LVMI as the single primary endpoint at 6 months and no placebo/sham arm. The FDA confirmed no additional nonclinical bridging studies are required and the company may use its commercial-scale Sf9-baculovirus process. Study initiation is on track for Q2 2026, with topline data expected in 2H 2027 and BLA submission under accelerated approval in 1H 2028.

LX2006: FDA open to pooled Phase I/II + pivotal data for BLA

FDA signaled willingness to accept pooled Phase I/II data plus pivotal-trial data for an accelerated-approval BLA and to assess the co-primary LVMI endpoint earlier than 12 months. FDA also approved the HEK-to-Sf9 manufacturing comparability report, clearing the way to use the final commercial Sf9 process in the registrational study. Lexeo now plans to initiate the pivotal trial in H1 2026.

Lexeo: FDA open to pooling Phase I/II data for LX2006 accelerated approval

FDA agreed to evaluate a BLA submission that pools LVMI data from ongoing Phase I/II studies with new pivotal-study data, and to assess the LVMI co-primary endpoint at an earlier time point than 12 months. Lexeo will submit enhanced manufacturing comparability data and meet one additional nonclinical requirement before starting the pivotal trial. Interim data show mean LVMI reductions of 18% at 6 months and 23% at 12 months in participants with abnormal baseline LVMI, exceeding the 10% threshold.